)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
NextCell Pharma
NextCell Pharma (NXTCL) investor relations material
NextCell Pharma Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary27 Aug, 2026
Executive summary
Launched first commercial product, NextCell-Cord RUO, in partnership with FUJIFILM Biosciences, expanding global reach.
Strengthened presence in Asia with new office in Hong Kong and participation in EU-Japan Biotech Business Mission.
Awaiting comprehensive data readout from ProTrans-Young clinical study in type 1 diabetes.
Continued development of NXTCL platform and strategic rebranding of drug candidates.
Financial highlights
Operating income for Q2 2026 was SEK 3.0 million, up from SEK 1.5 million year-over-year.
Net income for Q2 2026 was SEK -11.7 million, compared to SEK -11.2 million in Q2 2025.
Cash and cash equivalents at quarter-end were SEK 21.1 million, down from SEK 46.9 million a year earlier.
Earnings per share for Q2 2026 were SEK -0.09, improved from SEK -0.13 in Q2 2025.
Total cash flow for Q2 2026 was SEK -11.2 million, compared to SEK 24.8 million in Q2 2025.
Outlook and guidance
Focus on commercial execution of the TD1 program and expansion of manufacturing capabilities.
Anticipates further clinical data from ProTrans-Young to support treatment efficacy in type 1 diabetes.
Strategy includes building international partnerships and strengthening clinical and commercial foundations.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from NextCell Pharma
- Cash position strengthened by share issue despite increased operating loss and lower sales.NXTCL
Q1 2026 - ProTrans clinical progress, international expansion, and stable liquidity highlight the period.NXTCLTransition period
- ProTrans shows durable efficacy in diabetes, with global expansion and new indications ahead.NXTCLLife Science Summit 2025
- Losses narrowed and revenues grew as clinical and operational milestones were reached.NXTCLQ4 2025
- Net loss narrowed year-over-year as funding and partnerships strengthened clinical progress.NXTCLQ3 2025
- ProTrans clinical progress and successful capital raise position NextCell for future growth.NXTCLQ4 2024
- Rights issue oversubscribed, raising SEK 40.1M to fund ProTrans trials and operations.NXTCLQ3 2024
- ProTrans-Young shows strong safety but unclear efficacy after one year; long-term data awaited.NXTCLStudy Result
- ProTrans advances in diabetes, Cellaviva and QVance drive growth, losses narrow.NXTCLQ1 2025
Next NextCell Pharma earnings date
Q3 202626 Nov, 2026
NextCell Pharma
Next NextCell Pharma earnings date
Q3 202626 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
NextCell Pharma AB is a Swedish biopharmaceutical company specializing in the development of novel stromal cell therapies, primarily focusing on treatments for autoimmune and inflammatory diseases. Its flagship product, ProTrans, targets type 1 diabetes. The company also operates Cellaviva, the largest private stem cell bank in Scandinavia, which stores and processes stem cells from umbilical cords. NextCell Pharma integrates both therapeutic development and biobanking services within its operations. The company is headquartered in Huddinge, Sweden, and its shares are listed on the Nasdaq Stockholm.